Inovio Pharmaceuticals Inc. (INO) News
Filter INO News Items
INO News Results
|Loading, please wait...|
INO News Highlights
- For INO, its 30 day story count is now at 5.
- Over the past 13 days, the trend for INO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about INO are DNA, MRNA and RACE.
Latest INO News From Around the Web
Below are the latest news stories about Inovio Pharmaceuticals Inc that investors may wish to consider to help them evaluate INO as an investment opportunity.
The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Ocugen jumped into the race to develop a vaccine for COVID-19 by partnering up with Bharat Biotech, an India-based biotech company. Bharat Biotech ran a late-stage clinical trial for the vaccine in question, Covaxin, in India, and earned emergency use authorization (EUA) for it there.
immunotherapy programs for infectious diseases. Most of the focus so far, however, has been on the Covid-19 program for INO-4800.
Jefferies analyst Roger Song assumed coverage of Inovio Pharmaceuticals (INO -2.4%) with a Hold rating and price target (PT) of $6, down from $8. The analyst believes near-term stock movement will likely be driven by the company's COVID-19 program and he's cautious on the Phase 3 efficacy results of experimental...
Vontobel Holding Ltd. raised its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 69.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 189,556 shares of the biopharmaceutical company’s stock after acquiring an additional 77,800 shares during the period. Vontobel Holding Ltd.’s holdings in Inovio Pharmaceuticals were worth $1,357,000 as of its most recent […]
Is INO stock a buy after the Food and Drug Administration removed a hold barring the Inovio from testing its Covid vaccine in the U.S.?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares, rose in value on Friday, 12/17/21, with the stock price up by 8.51% to the previous days close as strong demand from buyers drove the stock to $6.50. Actively observing the price movement in the last trading, the stock closed the session at $5.99, falling within a range of $5.90 Inovio Pharmaceuticals Inc. (NASDAQ: INO) Has Outstanding Potential Read More »
NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local ...
Inovio (INO) made a big splash last year with its Covid-19 DNA vaccine candidate INO-4800. Development, however, has been slow, and the vaccine is still a while away from entering the market, should it ever get that far. In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le